<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="(SARS-CoV) and also with the novel coronavirus, SARS-CoV-2, which causes" exact="infection" post="and subsequent acute lung and probably heart injury [COVID-19"/>
 <result pre="an ARB (https://clinicaltrials.gov/ct2/show/NCT04312009). A second is investigating the outcomes of" exact="treatment" post="of COVID-19 patients with ACEIs or ARBs (https://clinicaltrials.gov/ct2/show/NCT04331574). Coronaviruses"/>
 <result pre="the world. SARS-CoV-2 is already responsible for more cases of" exact="infection" post="and also more deaths than the two previous coronavirus"/>
 <result pre="comorbidities in patients with COVID-19 (23). The increase in the" exact="prevalence" post="of these two comorbidities in patients with severe disease"/>
 <result pre="the use of drugs that block the RAS in the" exact="treatment" post="of hypertensive patients who have COVID-19 (25). This debate"/>
 <result pre="dilemma concerning the use of RAS blocking drugs in the" exact="treatment" post="of hypertension and diabetes. This is because while they"/>
 <result pre="young people are more likely to get the SARS coronavirus" exact="infection" post="than older people, as appears to be the case."/>
 <result pre="injury. Xie et al. suggest that there is a greater" exact="prevalence" post="of SARS-CoV in young people because they have higher"/>
 <result pre="of pulmonary ACE2, they should be more susceptible to symptomatic" exact="infection" post="with coronaviruses. The prevalence of infection is however based"/>
 <result pre="should be more susceptible to symptomatic infection with coronaviruses. The" exact="prevalence" post="of infection is however based on the appearance of"/>
 <result pre="more susceptible to symptomatic infection with coronaviruses. The prevalence of" exact="infection" post="is however based on the appearance of symptoms and"/>
 <result pre="in the young, the disease is usually so mild that" exact="infection" post="rates appear to be low. In fact, the milder"/>
 <result pre="expected from the known actions of ACE2, that this viral" exact="infection" post="was associated with raised Ang II levels, which caused"/>
 <result pre="coronavirus infections. While it is most advisable to prevent viral" exact="infection" post="and reduce the viral load, prevention of coronavirus-associated lung"/>
 <result pre="induced injury. ARBs would prevent downregulation of this pathway once" exact="infection" post="has occurred and ameliorate any unopposed pro-inflammatory effects of"/>
 <result pre="lung injury. Treating Coronavirus-Induced Lung Injury The major problem facing" exact="treatment" post="of coronavirus-induced lung and probably cardiac injury is that"/>
 <result pre="COVID-19 support the use of RAS blocking drugs in the" exact="treatment" post="of this infection (8, 9). Other alternatives, as suggested"/>
 <result pre="use of RAS blocking drugs in the treatment of this" exact="infection" post="(8, 9). Other alternatives, as suggested by Imai et"/>
 <result pre="to test the efficacy of ARBs and ACEIs in the" exact="treatment" post="of acute lung injury induced by SARS-CoV-2 is welcome"/>
 <result pre="al.. ACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epithelia. J Virol."/>
</results>
